[{"orgOrder":0,"company":"PolyPid","sponsor":"Aurum Ventures","pharmaFlowCategory":"D","amount":"$58.0 million","upfrontCash":"Undisclosed","newsHeadline":"Surgical Infection Biotech PolyPid Refiles for a $58 Million IPO","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Public Offering","leadProduct":"Doxycycline Hyclate","moa":"MMP-8","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0.059999999999999998,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"PolyPid \/ Aurum Ventures","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Aurum Ventures"},{"orgOrder":0,"company":"PolyPid","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PolyPid Initiates SHIELD II: Second Phase 3 Clinical Trial of D-PLEX\u2081\u2080\u2080 for the Prevention of Post-Abdominal Surgery Incisional Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Doxycycline Hyclate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"extended release Sterile powder for paste","sponsorNew":"PolyPid \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Not Applicable"},{"orgOrder":0,"company":"PolyPid","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PolyPid Announces 750th Patient Enrolled in SHIELD I Phase 3 Clinical Trial of D-PLEX\u2081\u2080\u2080 in Abdominal Surgery","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Doxycycline Hyclate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"","sponsorNew":"PolyPid \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Not Applicable"},{"orgOrder":0,"company":"PolyPid","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PolyPid to Deliver Poster Presentation at SAGES 2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Doxycycline Hyclate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Extended Release Sterile Powder For Paste","sponsorNew":"PolyPid \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Not Applicable"},{"orgOrder":0,"company":"PolyPid","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PolyPid Announces Presentation at the 13th European and Global CLINAM Summit for Nanomedicine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Doxycycline Hyclate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Extended-release Powder for Paste","sponsorNew":"PolyPid \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Not Applicable"},{"orgOrder":0,"company":"PolyPid","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PolyPid Announces Completion of Enrollment in Phase 3 SHIELD I Trial of D-PLEX\u2081\u2080\u2080 for Prevention of Surgical Site Infections in Abdominal Surgery","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Doxycycline Hyclate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Powder, Extended Release","sponsorNew":"PolyPid \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Not Applicable"},{"orgOrder":0,"company":"PolyPid","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PolyPid Announces Presentation of Phase 2 D-PLEX Clinical Data at the Midwest Surgical Association 2022 Annual Meeting","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Doxycycline Hyclate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Powder, Extended Release","sponsorNew":"PolyPid \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Not Applicable"},{"orgOrder":0,"company":"PolyPid","sponsor":"Advanz Pharma","pharmaFlowCategory":"D","amount":"$112.5 million","upfrontCash":"$2.6 million","newsHeadline":"PolyPid Announces Exclusive Licensing Agreement with ADVANZ PHARMA for the Commercialization of D-PLEX\u2081\u2080\u2080 in Europe","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Doxycycline Hyclate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0.11,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0.11,"dosageForm":"Powder, Extended Release","sponsorNew":"PolyPid \/ ADVANZ PHARMA","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ ADVANZ PHARMA"},{"orgOrder":0,"company":"PolyPid","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PolyPid Announces Top-line Results of Phase 3 SHIELD I Trial of D-PLEX\u2081\u2080\u2080 for the Prevention of Surgical Site Infections in Abdominal Surgery","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Doxycycline Hyclate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Powder, Extended Release","sponsorNew":"PolyPid \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Not Applicable"},{"orgOrder":0,"company":"PolyPid","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PolyPid Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results for D-PLEX\u2081\u2080\u2080 in the Prevention of Surgical Site Infections in Abdominal Surgery","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Doxycycline Hyclate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Powder, Extended Release","sponsorNew":"PolyPid \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Not Applicable"},{"orgOrder":0,"company":"PolyPid","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PolyPid Announces Eligibility for European Medicines Agency Centralized Procedure for D-PLEX\u2081\u2080\u2080 for the Prevention of Surgical Site Infections in Abdominal Surgery","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Doxycycline Hyclate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Powder, Extended Release","sponsorNew":"PolyPid \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Not Applicable"},{"orgOrder":0,"company":"PolyPid","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PolyPid Announces Presentation of Phase 2 D-PLEX\u2081\u2080\u2080 Clinical Data at the First Triennial Meeting of the International Orthopaedic Trauma Association","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Doxycycline Hyclate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Powder, Extended Release","sponsorNew":"PolyPid \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Not Applicable"},{"orgOrder":0,"company":"PolyPid","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PolyPid Announces Scheduling of Type D Meeting with U.S. FDA to Discuss SHIELD I Phase 3 Results and Regulatory Pathway for D-PLEX\u2081\u2080\u2080 for the Prevention of Surgical Site Infections in Abdominal Colorectal Surgery","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Doxycycline Hyclate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Powder, Extended Release","sponsorNew":"PolyPid \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Not Applicable"},{"orgOrder":0,"company":"PolyPid","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PolyPid Announces Presentation of D-PLEX\u201a\u0081Phase 2 Clinical Data at ASM Microbe 2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Doxycycline Hyclate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Powder, Extended Release","sponsorNew":"PolyPid \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Not Applicable"},{"orgOrder":0,"company":"PolyPid","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PolyPid Announces Publication in the American Journal of Surgery of Phase 2 Clinical Trial Post-hoc Analysis for D-PLEX-100 in the Prevention of Surgical Site Infections in Abdominal Surgery","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Doxycycline Hyclate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Powder, Extended Release","sponsorNew":"PolyPid \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Not Applicable"},{"orgOrder":0,"company":"PolyPid","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PolyPid Provides Positive Regulatory Update for D-PLEX\u2081\u2080\u2080 for the Prevention of Surgical Site Infections in Abdominal Colorectal Surgery","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Doxycycline Hyclate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Powder, Extended Release","sponsorNew":"PolyPid \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Not Applicable"},{"orgOrder":0,"company":"PolyPid","sponsor":"Newbridge Securities Corporation","pharmaFlowCategory":"D","amount":"$6.2 million","upfrontCash":"Undisclosed","newsHeadline":"PolyPid Announces Pricing of $6.2 Million Underwritten Public Offering of Ordinary Shares and Concurrent $4.4 Million Private Placement of Pre-Funded Warrants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Public Offering","leadProduct":"Doxycycline Hyclate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0.01,"dosageForm":"","sponsorNew":"PolyPid \/ Newbridge Securities Corporation","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Newbridge Securities Corporation"},{"orgOrder":0,"company":"PolyPid","sponsor":"Newbridge Securities Corporation","pharmaFlowCategory":"D","amount":"$4.4 million","upfrontCash":"Undisclosed","newsHeadline":"PolyPid Announces Pricing of $6.2 Million Underwritten Public Offering of Ordinary Shares and Concurrent $4.4 Million Private Placement of Pre-Funded Warrants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Private Placement","leadProduct":"Doxycycline Hyclate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"","sponsorNew":"PolyPid \/ Newbridge Securities Corporation","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Newbridge Securities Corporation"},{"orgOrder":0,"company":"PolyPid","sponsor":"Newbridge Securities Corporation","pharmaFlowCategory":"D","amount":"$7.1 million","upfrontCash":"Undisclosed","newsHeadline":"PolyPid Announces Closing of Underwritten Public Offering, Including Full Exercise of Overallotment Option, and Concurrent Private Placement with $11.4 Million in Aggregate Gross Proceeds","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Public Offering","leadProduct":"Doxycycline Hyclate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0.01,"dosageForm":"","sponsorNew":"PolyPid \/ Newbridge Securities Corporation","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Newbridge Securities Corporation"},{"orgOrder":0,"company":"PolyPid","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PolyPid Announces FDA Agreement on the Design of SHIELD II Phase 3 Trial Evaluating D-PLEX\u2081\u2080\u2080 for Prevention of Abdominal Colorectal Surgical Site Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Doxycycline Hyclate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Powder, Extended Release","sponsorNew":"PolyPid \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Not Applicable"},{"orgOrder":0,"company":"PolyPid","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PolyPid Announces Recruitment of First Patient in Revised SHIELD II Phase 3 Trial Evaluating D-PLEX-100 for Prevention of Abdominal Colorectal Surgical Site Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Doxycycline Hyclate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Powder, Extended Release","sponsorNew":"PolyPid \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Not Applicable"},{"orgOrder":0,"company":"PolyPid","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PolyPid Announces Successful Completion of Manufacturing Process Validation for D-PLEX\u2081\u2080\u2080","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Doxycycline Hyclate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Powder, Extended Release","sponsorNew":"PolyPid \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Not Applicable"},{"orgOrder":0,"company":"PolyPid","sponsor":"JMP Securities","pharmaFlowCategory":"D","amount":"$16.2 million","upfrontCash":"Undisclosed","newsHeadline":"PolyPid Announces Private Placement for $16 Million in Gross Proceeds","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Private Placement","leadProduct":"Doxycycline Hyclate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0.02,"dosageForm":"Paste","sponsorNew":"PolyPid \/ JMP Securities","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ JMP Securities"},{"orgOrder":0,"company":"PolyPid","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PolyPid Enrolls 200th Patient in SHIELD II Trial for D-PLEX\u2081\u2080\u2080 Against Surgical Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Doxycycline Hyclate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Paste","sponsorNew":"PolyPid \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Not Applicable"},{"orgOrder":0,"company":"PolyPid","sponsor":"Citizens JMP","pharmaFlowCategory":"D","amount":"$14.0 million","upfrontCash":"Undisclosed","newsHeadline":"PolyPid Announces Private Placement for Up to $14 Million in Gross Proceeds","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2024","year":"2024","type":"Private Placement","leadProduct":"Doxycycline Hyclate","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"","graph3":"PolyPid","amount2":0.01,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"","highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"PolyPid \/ Citizens JMP","highestDevelopmentStatusID":"13","companyTruncated":"PolyPid \/ Citizens JMP"},{"orgOrder":0,"company":"PolyPid","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PolyPid Announces Last Patient in For SHIELD II Phase 3 Trial Evaluating D-PLEX","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Doxycycline Hyclate","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"PolyPid","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PolyPid \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"PolyPid \/ Not Applicable"}]
Find Clinical Drug Pipeline Developments & Deals for Doxycycline Hyclate
Details :
D-PLEX100, an extended-release doxycycline hyclate formulation, is currently evaluated for preventing surgical site infections in patients undergoing abdominal colorectal surgery.
Details :
The company intends to use the net proceeds from the financing for its ongoing SHIELD IIlate-stage clinical trial studies D-PLEX100 (doxycycline hyclate) for the treatment of surgical site infections.
Details :
The company intends to use net proceeds for the SHIELD II phase 3 clinical trial, evaluating D-PLEX100 (extended release doxycycline hyclate) for preventing infections in colorectal surgery patients.
Details :
D-PLEX100 (doxycycline hyclate) is polyPid’s lead product candidate, designed to provide local prolonged and controlled anti-bacterial activity directly at the surgical site to prevent SSIs.
Details :
D-PLEX100 (doxycycline hyclate) is polyPid’s lead product candidate, designed to provide local prolonged and controlled anti-bacterial activity directly at the surgical site to prevent SSIs.
Details :
D-PLEX100 (doxycycline hyclate) is polyPid’s lead product candidate, designed to provide local prolonged and controlled anti-bacterial activity directly at the surgical site to prevent SSIs.
Details :
PolyPid intends to use the net proceeds from the Public Offering to fund the ongoing clinical activities and development of D-PLEX100 (doxycycline hyclate). D-PLEX100 is in Phase 3 clinical trials for the prevention of abdominal colorectal surgical site ...
Details :
PolyPid intends to use the net proceeds from the Public Offering to fund the ongoing clinical activities and development of D-PLEX100 (doxycycline hyclate). D-PLEX100 is in Phase 3 clinical trials for the prevention of abdominal colorectal surgical site ...
Details :
PolyPid intends to use the net proceeds from the private placement to fund the ongoing clinical activities and development of D-PLEX100 (doxycycline hyclate). D-PLEX100 is in Phase 3 clinical trials for the prevention of abdominal colorectal surgical sit...
Market Place
Reset All
